Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-01-01 @ 12:06 PM
Study NCT ID:
NCT01837251
Status:
COMPLETED
Last Update Posted:
2021-07-13
First Post:
2013-04-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Sponsor:
AGO Research GmbH
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AGO-OVAR 2.21 / ENGOT ov-18
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None